Sutent for paragagnlioma – pro
Paraganglioma is rare cancer and most of what is known about how to treat it comes from case reports and small case series. The optimal systemic treatment for advanced disease is undefined, due in part to lack of effective agents. There are several reports of tens of patients suggesting that Sutent is an active agent for this condition. A 2017 report and literature review (Canu et al) says: ” Sunitinib seems able to slow the disease progression in some patients with malignant PHEO/PGL and therefore may represent a therapeutic option, although randomized controlled studies are needed to assess its efficacy definitively in the treatment of these aggressive tumors.”.
Joshua AM et al, Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.J Clin Endocrinol Metab. 2009 Jan;94(1):5-9.
Canu L et al, Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature. Arch Endocrinol Metab. 2017 Jan-Feb;61(1):90-97.